MK-2206
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PANCREAS
Conditions
PANCREAS, Neuroendocrine
Trial Timeline
Jul 1, 2010 → Feb 1, 2014
NCT ID
NCT01169649About MK-2206
MK-2206 is a phase 2 stage product being developed by Merck for PANCREAS. The current trial status is completed. This product is registered under clinical trial identifier NCT01169649. Target conditions include PANCREAS, Neuroendocrine.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01249105 | Phase 2 | Withdrawn |
| NCT01186705 | Phase 2 | Terminated |
| NCT01169649 | Phase 2 | Completed |
| NCT00670488 | Phase 1 | Completed |
Competing Products
20 competing products in PANCREAS